
    
      This is a multicenter, randomized, double-blind, placebo- and active-controlled trial to
      evaluate the safety and efficacy of brexpiprazole monotherapy compared to placebo in
      adolescent subjects (ages 13-17) with a DSM-5 diagnosis of schizophrenia.
    
  